1-12 of 12
Frank G. Haluska, MD, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Efficacy and Safety Of Ponatinib Following Failure Of Nilotinib In Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML) In The PACE Trial

Hagop M. Kantarjian, MD, Jorge E. Cortes, MD, Dong-Wook Kim, MD, PhD, Javier Pinilla-Ibarz, MD, PhD, Philipp D. le Coutre, MD, Ronald Paquette, MD, Charles Chuah, MD, Franck E. Nicolini, MD, PhD, Jane F. Apperley, MD, H Jean Khoury, MD, Moshe Talpaz, MD, John F. DiPersio, MD, PhD, Daniel J. DeAngelo, MD, PhD, Elisabetta Abruzzese, MD, PhD, Delphine Rea, MD, PhD, Michele Baccarani, MD, Martin C. Müller, MD, Carlo Gambacorti-Passerini, MD, Stephanie Lustgarten, PhD, Victor M. Rivera, PhD, Tim Clackson, PhD, Christopher D. Turner, MD, Frank G. Haluska, MD, PhD, Francois Guilhot, MD, Michael W. Deininger, Andreas Hochhaus, MD, Timothy P. Hughes, MD, MBBS, John M. Goldman, MD, Neil P. Shah, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 2738.
https://doi.org/10.1182/blood.V122.21.2738.2738
Published: 2013
Journal Articles

Clinical Impact Of Dose Modification On Response To Ponatinib In Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML)

Javier Pinilla-Ibarz, MD, PhD, Jorge E. Cortes, MD, Dong-Wook Kim, MD, PhD, Philipp D. Le Coutre, MD, Ronald Paquette, MD, Charles Chuah, MD, Franck E. Nicolini, MD, PhD, Jane F Apperley, MD, H. Jean Khoury, MD, John F. Dipersio, MD, PhD, Daniel J DeAngelo, MD, PhD, Elisabetta Abruzzese, MD, PhD, Delphine Rea, MD, PhD, Michele Baccarani, MD, Martin C Muller, MD, Carlo Gambacorti-Passerini, MD, Stephanie Lustgarten, PhD, Victor M. Rivera, PhD, Tim Clackson, PhD, Christopher D Turner, MD, Frank G Haluska, MD, PhD, Francois Guilhot, MD, Michael W. Deininger, MD, PhD, Andreas Hochhaus, MD, Timothy P. Hughes, MD, MBBS, John M Goldman, DM, Neil P. Shah, MD, PhD, Hagop M. Kantarjian, MD, Moshe Talpaz, MD
Journal: Blood
Blood (2013) 122 (21): 4007.
https://doi.org/10.1182/blood.V122.21.4007.4007
Published: 2013
Journal Articles

Ponatinib In Heavily Pretreated Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML): Management Of Adverse Events (AEs)

Philipp D. Le Coutre, MD, Dong-Wook Kim, MD, PhD, Javier Pinilla-Ibarz, MD, PhD, Ronald Paquette, MD, Charles Chuah, MD, Franck E. Nicolini, MD, PhD, Jane F Apperley, MD, H. Jean Khoury, MD, Moshe Talpaz, MD, John F. Dipersio, MD, PhD, Daniel J DeAngelo, MD, PhD, Elisabetta Abruzzese, MD, PhD, Delphine Rea, MD, PhD, Michele Baccarani, MD, Martin C Muller, MD, Carlo Gambacorti-Passerini, MD, Stephanie Lustgarten, PhD, Kumiko Yanase, MD, PhD, Christopher D Turner, MD, Frank G Haluska, MD, PhD, Francois Guilhot, MD, Michael W. Deininger, MD, PhD, Andreas Hochhaus, MD, Timothy P. Hughes, MD, MBBS, John M Goldman, DM, Neil P. Shah, MD, PhD, Hagop M. Kantarjian, MD, Jorge E. Cortes, MD
Journal: Blood
Blood (2013) 122 (21): 1496.
https://doi.org/10.1182/blood.V122.21.1496.1496
Published: 2013
Journal Articles

Efficacy and Safety Of Ponatinib Following Failure Of Dasatinib In Patients (pts) With Chronic Phase Chronic Myeloid Leukemia (CP-CML) In The PACE Trial

Andreas Hochhaus, MD, Jorge E. Cortes, MD, Dong-Wook Kim, MD, PhD, Javier Pinilla-Ibarz, MD, PhD, Philipp D le Coutre, MD, Ronald Paquette, MD, Charles Chuah, MD, Franck E. Nicolini, MD, PhD, Jane F Apperley, MD, H. Jean Khoury, MD, Moshe Talpaz, MD, John F. DiPersio, MD, PhD, Daniel J DeAngelo, MD, PhD, Elisabetta Abruzzese, MD, PhD, Delphine Rea, MD, PhD, Michele Baccarani, MD, Martin C. Müller, MD, Carlo Gambacorti-Passerini, MD, Stephanie Lustgarten, PhD, Victor M. Rivera, PhD, Tim Clackson, PhD, Christopher D Turner, MD, Frank G Haluska, MD, PhD, Michael W. Deininger, MD, PhD, Timothy P. Hughes, MD, MBBS, John M Goldman, MD, Neil P. Shah, MD, PhD, Hagop M. Kantarjian, MD, François Guilhot, MD
Journal: Blood
Blood (2013) 122 (21): 1498.
https://doi.org/10.1182/blood.V122.21.1498.1498
Published: 2013
Journal Articles

Ponatinib In Patients (pts) With Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Resistant Or Intolerant To Dasatinib Or Nilotinib, Or With The T315I BCR-ABL Mutation: 2-Year Follow-Up Of The PACE Trial

Jorge E. Cortes, MD, Dong-Wook Kim, MD, PhD, Javier Pinilla-Ibarz, MD, PhD, Philipp D le Coutre, MD, Ronald Paquette, MD, Charles Chuah, MD, Franck E. Nicolini, MD PhD, Jane F Apperley, MD, H. Jean Khoury, MD, Moshe Talpaz, MD, John F. DiPersio, MD, PhD, Daniel J DeAngelo, MD, PhD, Elisabetta Abruzzese, MD, PhD, Delphine Rea, MD, PhD, Michele Baccarani, MD, Martin C. Müller, MD, Carlo Gambacorti-Passerini, MD, Stephanie Lustgarten, PhD, Victor M. Rivera, PhD, Tim Clackson, PhD, Christopher D Turner, MD, Frank G Haluska, MD, PhD, François Guilhot, MD, Michael W. Deininger, MD, PhD, Andreas Hochhaus, MD, Timothy P. Hughes, MD, MBBS, John M Goldman, MD, Neil P. Shah, MD, PhD, Hagop M. Kantarjian, MD
Journal: Blood
Blood (2013) 122 (21): 650.
https://doi.org/10.1182/blood.V122.21.650.650
Published: 2013
Journal Articles

Impact Of Baseline (BL) Mutations, Including Low-Level and Compound Mutations, On Ponatinib Response and End Of Treatment (EOT) Mutation Analysis In Patients (Pts) With Chronic Phase Chronic Myeloid Leukemia (CP-CML)

Michael W. Deininger, MD, PhD, Neil P. Shah, MD, PhD, Jorge E. Cortes, MD, Dong-Wook Kim, MD, PhD, Franck E. Nicolini, MD, PhD, Moshe Talpaz, MD, Michele Baccarani, MD, Martin C Muller, MD, Jin Li, Stephanie Lustgarten, PhD, Tim Clackson, PhD, Christopher D Turner, MD, Frank G Haluska, MD, PhD, Graeme Hodgson, PhD, Victor M. Rivera, PhD, Francois Guilhot, MD, John M Goldman, DM, Hagop M. Kantarjian, MD, Simona Soverini, Andreas Hochhaus, MD, Timothy P. Hughes, MD, MBBS, Susan Branford, PhD
Journal: Blood
Blood (2013) 122 (21): 652.
https://doi.org/10.1182/blood.V122.21.652.652
Published: 2013
Journal Articles

A Pivotal Phase 2 Trial of Ponatinib in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Resistant or Intolerant to Dasatinib or Nilotinib, or with the T315I BCR-ABL Mutation: 12-Month Follow-up of the PACE Trial

Jorge E. Cortes, MD, Dong-Wook Kim, MD, Javier Pinilla-Ibarz, MD, PhD, Philipp le Coutre, MD, Ron Paquette, MD, PhD, Charles Chuah, MD, Franck E Nicolini, MD, PhD, Jane Apperley, H. Jean Khoury, Moshe Talpaz, MD, John F. DiPersio, MD, PhD, Daniel J. DeAngelo, MD, PhD, Elisabetta Abruzzese, Delphine Rea, MD, PhD, Michele Baccarani, MD, Martin C Muller, Carlo Gambacorti-Passerini, MD, Stephane Wong, PhD, Stephanie Lustgarten, Victor M. Rivera, PhD, Tim Clackson, PhD, Christopher D. Turner, MD, FAAP, Frank G Haluska, MD, PhD, Francois Guilhot, MD, Michael W. Deininger, MD, PhD, Andreas Hochhaus, MD, Timothy Hughes, John M Goldman, MD, Neil Shah, MD, PhD, Hagop M Kantarjian, M.D., The PACE Study Group
Journal: Blood
Blood (2012) 120 (21): 163.
https://doi.org/10.1182/blood.V120.21.163.163
Published: 2012
Journal Articles

Efficacy and Safety of Ponatinib in Patients with Accelerated Phase or Blast Phase Chronic Myeloid Leukemia (AP-CML or BP-CML) or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): 12-Month Follow-up of the PACE Trial

Hagop M. Kantarjian, MD, Dong-Wook Kim, Javier Pinilla-Ibarz, MD, PhD, Philipp le Coutre, MD, Ronald Paquette, MD, PhD, Charles Chuah, MD, Franck E. Nicolini, MD, PhD, Jane Apperley, H. Jean Khoury, MD, Moshe Talpaz, MD, John F. DiPersio, MD, PhD, Daniel DeAngelo, MD, Elisabetta Abruzzese, MD, PhD, Delphine Rea, MD, PhD, Michele Baccarani, MD, Martin C Muller, MD, Carlo Gambacorti-Passerini, MD, Stephane Wong, PhD, Stephanie Lustgarten, Victor M. Rivera, PhD, Tim Clackson, PhD, Christopher D. Turner, MD, FAAP, Frank G Haluska, MD, PhD, Francois Guilhot, Michael W. Deininger, MD, PhD, Andreas Hochhaus, MD, Timothy P. Hughes, MD, MBBS, John Goldman, DM, FRCP, FRCPath, FMedSci, Neil Shah, MD, PhD, Jorge E. Cortes, MD, The PACE Study Group
Journal: Blood
Blood (2012) 120 (21): 915.
https://doi.org/10.1182/blood.V120.21.915.915
Published: 2012
Journal Articles

Efficacy and Safety of Ponatinib According to Prior Approved Tyrosine Kinase Inhibitor (TKI) Therapy in Patients with Chronic Myeloid Leukemia in Chronic Phase (CP-CML): Results From the PACE Trial

Dong-Wook Kim, Jorge E. Cortes, MD, Javier Pinilla-Ibarz, MD, PhD, Philipp le Coutre, MD, Ronald Paquette, MD, PhD, Charles Chuah, MD, Franck E. Nicolini, MD, PhD, Jane Apperley, H. Jean Khoury, Moshe Talpaz, MD, John F. DiPersio, MD, PhD, Daniel DeAngelo, MD, Elisabetta Abruzzese, MD, PhD, Delphine Rea, MD, PhD, Michele Baccarani, MD, Martin C Muller, MD, Carlo Gambacorti-Passerini, MD, Stephane Wong, PhD, Stephanie Lustgarten, Victor M. Rivera, PhD, Tim Clackson, PhD, Christopher D. Turner, MD, FAAP, Frank G Haluska, MD, PhD, Francois Guilhot, Michael W. Deininger, MD, PhD, Andreas Hochhaus, MD, Timothy P. Hughes, MD, MBBS, John M Goldman, MD, Neil Shah, MD, PhD, Hagop M. Kantarjian, MD, The PACE Study Group
Journal: Blood
Blood (2012) 120 (21): 3749.
https://doi.org/10.1182/blood.V120.21.3749.3749
Published: 2012
Journal Articles

Molecular Responses with Ponatinib in Patients with Philadelphia Chromosome Positive (Ph+) Leukemia: Results From the PACE Trial

Andreas Hochhaus, MD, Dong-Wook Kim, Javier Pinilla-Ibarz, MD, PhD, Philipp le Coutre, MD, Ronald Paquette, MD, PhD, Charles Chuah, MD, Franck E. Nicolini, MD, PhD, Jane Apperley, H. Jean Khoury, MD, Moshe Talpaz, MD, John F. DiPersio, MD, PhD, Daniel DeAngelo, MD, Elisabetta Abruzzese, MD, PhD, Delphine Rea, MD, PhD, Michele Baccarani, Martin C Muller, MD, Carlo Gambacorti-Passerini, Stephane Wong, PhD, Stephanie Lustgarten, Victor M. Rivera, PhD, Tim Clackson, PhD, Christopher D. Turner, MD, FAAP, Frank G Haluska, MD, PhD, Francois Guilhot, Michael W. Deininger, MD, PhD, Timothy P. Hughes, MD, MBBS, John M Goldman, MD, Neil Shah, MD, PhD, Hagop M. Kantarjian, MD, Jorge E. Cortes, MD, The PACE Study Group
Journal: Blood
Blood (2012) 120 (21): 3763.
https://doi.org/10.1182/blood.V120.21.3763.3763
Published: 2012
Journal Articles

Long-Term Anti-Leukemic Activity of Ponatinib in Patients with Philadelphia Chromosome-Positive Leukemia: Updated Results from an Ongoing Phase 1 Study

Michael W Deininger, MD, PhD, Jorge E. Cortes, MD, Hagop M. Kantarjian, MD, Neil Shah, MD, PhD, Dale Bixby, MD, PhD, Michael J. Mauro, MD, Ian W. Flinn, MD, PhD, Thomas O'Hare, PhD, Simin Hu, PhD, David J. Dorer, Victor M. Rivera, PhD, Tim Clackson, PhD, Christopher D. Turner, MD, FAAP, Frank G Haluska, MD, PhD, Brian J. Druker, Moshe Talpaz, MD
Journal: Blood
Blood (2012) 120 (21): 3743.
https://doi.org/10.1182/blood.V120.21.3743.3743
Published: 2012
Journal Articles

Multivariate Analyses of the Clinical and Molecular Parameters Associated with Efficacy and Safety in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Treated with Ponatinib in the PACE Trial

Michael J. Mauro, MD, Jorge E. Cortes, MD, Dong-Wook Kim, Javier Pinilla-Ibarz, MD, PhD, Philipp le Coutre, MD, Ronald Paquette, MD, PhD, Charles Chuah, MD, Franck E. Nicolini, MD, PhD, Jane Apperley, H. Jean Khoury, MD, FACP, Moshe Talpaz, MD, John F. DiPersio, MD, PhD, Daniel J DeAngelo, MD, PhD, Elisabetta Abruzzese, Delphine Rea, MD, PhD, Michele Baccarani, MD, Martin C Muller, MD, Carlo Gambacorti-Passerini, MD, Stephane Wong, PhD, David J. Dorer, Ronald Keith Knickerbocker, PhD, Victor M. Rivera, PhD, Tim Clackson, PhD, Christopher D. Turner, MD, FAAP, Frank G Haluska, MD, PhD, Francois Guilhot, Michael W. Deininger, MD, PhD, Andreas Hochhaus, MD, Timothy Hughes, MD, MBBS, John M Goldman, MD, Neil Shah, MD, PhD, Hagop M. Kantarjian, MD, The PACE Study Group
Journal: Blood
Blood (2012) 120 (21): 3747.
https://doi.org/10.1182/blood.V120.21.3747.3747
Published: 2012